EUCTR2021-002253-29-DE进行中（未招募）1 期
Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of ZED1227 capsules with placebo in the treatment of non-alcoholic fatty liver disease (NAFLD) with significant fibrosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Has provided signed informed consent
- •- Is a male or female = 18 and < 75 years of age
- •- Has diagnosed NAFLD
- •- Has diagnosed significant fibrosis (stages 2 or 3)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Has a history of significant alcohol consumption (an average of > 20 g/d in females and > 30 g/d in males)
- •- Has a history or presence of any other significant concomitant liver diseases
- •- Has diagnosed type 1 diabetes mellitus (T1DM)
- •- Has presence of cirrhosis
研究者
相似试验
进行中（未招募）
1 期
A study to compare norursodeoxycholic acid with placebo in the treatment of primary sclerosing cholangitisPrimary Sclerosing Cholangitis (PSC) is a slowly progressing chronic cholestatic liver disease of assumed autoimmune, but finally unidentified etiology, characterized by a chronic inflammatory and fibro-obliterative destruction of extra-, and intrahepatic bile ducts. The disease is characterized by diffuse inflammation, fibrosis, and strictures of the intra- and/or extrahepatic bile ducts with an impaired biliary secretion of potentially aggressive bile fluid often leading to cirrhosis.MedDRA version: 20.1 Level: LLT Classification code 10036732 Term: Primary sclerosing cholangitis System Organ Class: 100000004871EUCTR2016-003367-19-FRDr. Falk Pharma GmbH300
进行中（未招募）
1 期
Double-blind (neither physician nor patient knows of the actual treatment which can with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets in comparison with placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitisEUCTR2014-001485-99-DEDr. Falk Pharma GmbH204
进行中（未招募）
1 期
Double-blind (neither physician nor patient knows of the actual treatment which can with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets in comparison with placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitisMaintenance of remission in eosinophilic esophagitisMedDRA version: 20.1Level: LLTClassification code 10064220Term: Eosinophilic esophagitisSystem Organ Class: 100000004856EUCTR2014-001485-99-GBDr. Falk Pharma GmbH204
进行中（未招募）
1 期
A study to compare norursodeoxycholic acid with placebo in the treatment of primary sclerosing cholangitisEUCTR2016-003367-19-IEDr. Falk Pharma GmbH300
进行中（未招募）
1 期
A study to compare norursodeoxycholic acid with placebo in the treatment of primary sclerosing cholangitisPrimary Sclerosing Cholangitis (PSC) is a slowly progressing chronic cholestatic liver disease of assumed autoimmune, but finally unidentified etiology, characterized by a chronic inflammatory and fibro-obliterative destruction of extra-, and intrahepatic bile ducts. The disease is characterized by diffuse inflammation, fibrosis, and strictures of the intra- and/or extrahepatic bile ducts with an impaired biliary secretion of potentially aggressive bile fluid often leading to cirrhosis.MedDRA version: 20.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871EUCTR2016-003367-19-HUDr. Falk Pharma GmbH300